Danielle D. Jandial

Oncology

101 The City Dr S # 4
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

Journal: JCO precision oncology

Published: August 26, 2026

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Journal: NPJ precision oncology

Published: November 21, 2025

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors.

Journal: Molecular cancer therapeutics

Published: December 23, 2024

Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer.

Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer.

Journal: Advances in therapy

Published: April 28, 2021

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.

Journal: Spine

Published: October 10, 2020

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.

Journal: BMC cancer

Published: October 01, 2020

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 10, 2019

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.

Journal: The Lancet. Oncology

Published: March 07, 2019

Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology.

Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology.

Journal: Dentistry journal

Published: January 31, 2019

Epidemiology of benign giant cell tumor of bone in the Chinese population.

Epidemiology of benign giant cell tumor of bone in the Chinese population.

Journal: Journal of bone oncology

Published: March 01, 2018

Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.

Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.

Journal: Molecules (Basel, Switzerland)

Published: January 22, 2017

A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.

A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 28, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026